IL130897A0 - Atropisomers of 3-heteroaryl-4 (3H)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions - Google Patents

Atropisomers of 3-heteroaryl-4 (3H)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions

Info

Publication number
IL130897A0
IL130897A0 IL13089798A IL13089798A IL130897A0 IL 130897 A0 IL130897 A0 IL 130897A0 IL 13089798 A IL13089798 A IL 13089798A IL 13089798 A IL13089798 A IL 13089798A IL 130897 A0 IL130897 A0 IL 130897A0
Authority
IL
Israel
Prior art keywords
quinazolinones
atropisomers
neurodegenerative
cns
heteroaryl
Prior art date
Application number
IL13089798A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL130897A0 publication Critical patent/IL130897A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13089798A 1997-02-28 1998-02-06 Atropisomers of 3-heteroaryl-4 (3H)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions IL130897A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3854097P 1997-02-28 1997-02-28
PCT/IB1998/000151 WO1998038187A1 (en) 1997-02-28 1998-02-06 Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions

Publications (1)

Publication Number Publication Date
IL130897A0 true IL130897A0 (en) 2001-01-28

Family

ID=21900535

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13089798A IL130897A0 (en) 1997-02-28 1998-02-06 Atropisomers of 3-heteroaryl-4 (3H)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions

Country Status (40)

Country Link
US (1) US6380204B1 (xx)
EP (1) EP0964860B1 (xx)
JP (1) JP3299990B2 (xx)
KR (1) KR20000075812A (xx)
CN (1) CN1248254A (xx)
AP (1) AP9801202A0 (xx)
AR (1) AR011886A1 (xx)
AT (1) ATE264854T1 (xx)
AU (1) AU732448B2 (xx)
BG (1) BG103687A (xx)
BR (1) BR9807807A (xx)
CA (1) CA2282279C (xx)
CO (1) CO4950615A1 (xx)
DE (1) DE69823339T2 (xx)
DK (1) DK0964860T3 (xx)
DZ (1) DZ2438A1 (xx)
EA (1) EA001961B1 (xx)
ES (1) ES2218801T3 (xx)
GT (1) GT199800039A (xx)
HN (1) HN1998000028A (xx)
HR (1) HRP980108B1 (xx)
HU (1) HUP0000935A3 (xx)
ID (1) ID23435A (xx)
IL (1) IL130897A0 (xx)
IS (1) IS5141A (xx)
MA (1) MA24485A1 (xx)
NO (1) NO994178D0 (xx)
NZ (1) NZ336627A (xx)
OA (1) OA11088A (xx)
PA (1) PA8446901A1 (xx)
PE (1) PE57999A1 (xx)
PL (1) PL335307A1 (xx)
PT (1) PT964860E (xx)
SK (1) SK113199A3 (xx)
TN (1) TNSN98034A1 (xx)
TR (1) TR199902094T2 (xx)
TW (1) TW530055B (xx)
UA (1) UA58536C2 (xx)
WO (1) WO1998038187A1 (xx)
ZA (1) ZA981665B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323208B1 (en) 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
JPH11279158A (ja) * 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―4―オン誘導体の製造方法
US6890930B1 (en) * 1999-09-28 2005-05-10 3-Dimensional Pharmaceuticals, Inc. Quinazolinones
BRPI0413372A (pt) * 2003-08-08 2006-10-17 Ulysses Pharmaceutical Product composto e composições de nitrofuranos de quinazolinil halogenados, seus métodos de preparação e usos como agentes antibacterianos
US20080146562A1 (en) * 2003-08-08 2008-06-19 Ulysses Pharmaceutical Products Inc., Halogenated quinazolinyl nitrofurans as antibacterial agents
GB0416730D0 (en) 2004-07-27 2004-09-01 Novartis Ag Organic compounds
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
AU2006311883A1 (en) 2005-11-04 2007-05-18 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
CN101547922B (zh) * 2006-10-04 2012-06-20 辉瑞产品公司 作为钙受体拮抗剂的吡啶并[4,3-d]嘧啶-4(3H)-酮衍生物
WO2008140750A1 (en) * 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
BRPI1012333A2 (pt) * 2009-03-24 2016-03-29 Gilead Calistoga Llc atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
WO2010138577A1 (en) * 2009-05-29 2010-12-02 Merck Sharp & Dohme Corp. Radiolabeled pde10 inhibitors
WO2013105985A1 (en) * 2011-02-28 2013-07-18 Philadelphia Health & Education Corporation Small molecule inhibitors of rad51 recombinase and methods thereof
JP2023512664A (ja) 2020-01-29 2023-03-28 カマリ ファーマ リミテッド 皮膚障害の治療に使用するための化合物及び組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1298603A (en) 1970-04-06 1972-12-06 Karamchand Premchand Private Quinazolinone derivatives
US4183931A (en) 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
WO1992013535A1 (en) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Anticonvulsant substituted quinazolones
SK284108B6 (sk) 1996-05-15 2004-09-08 Pfizer Inc. 2,3-Disubstituované 4(3H)-chinazolinóny, ich použitie a farmaceutické kompozície s ich obsahom
EP0807633B1 (en) 1996-05-15 2002-11-06 Pfizer Inc. Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones

Also Published As

Publication number Publication date
AP9801202A0 (en) 1999-08-26
AU5775998A (en) 1998-09-18
US6380204B1 (en) 2002-04-30
ATE264854T1 (de) 2004-05-15
IS5141A (is) 1999-07-30
PE57999A1 (es) 1999-06-21
HRP980108A2 (en) 1998-12-31
ES2218801T3 (es) 2004-11-16
NO994178L (no) 1999-08-27
NZ336627A (en) 2000-12-22
OA11088A (en) 2002-03-15
PT964860E (pt) 2004-07-30
DK0964860T3 (da) 2004-07-26
TW530055B (en) 2003-05-01
TR199902094T2 (xx) 1999-12-21
JP2000509732A (ja) 2000-08-02
PL335307A1 (en) 2000-04-10
JP3299990B2 (ja) 2002-07-08
PA8446901A1 (es) 2000-05-24
CA2282279C (en) 2004-11-02
BR9807807A (pt) 2000-02-22
TNSN98034A1 (fr) 2005-03-15
MA24485A1 (fr) 1998-10-01
EP0964860A1 (en) 1999-12-22
UA58536C2 (uk) 2003-08-15
ZA981665B (en) 1999-08-17
AU732448B2 (en) 2001-04-26
DE69823339D1 (de) 2004-05-27
HRP980108B1 (en) 2004-10-31
EA001961B1 (ru) 2001-10-22
CN1248254A (zh) 2000-03-22
CA2282279A1 (en) 1998-09-03
GT199800039A (es) 1999-08-13
CO4950615A1 (es) 2000-09-01
DZ2438A1 (fr) 2003-01-11
KR20000075812A (ko) 2000-12-26
WO1998038187A1 (en) 1998-09-03
AR011886A1 (es) 2000-09-13
BG103687A (en) 2000-06-30
SK113199A3 (en) 2001-10-08
EA199900689A1 (ru) 2000-02-28
ID23435A (id) 2000-04-20
NO994178D0 (no) 1999-08-27
DE69823339T2 (de) 2005-05-12
HN1998000028A (es) 1999-02-09
EP0964860B1 (en) 2004-04-21
HUP0000935A2 (hu) 2001-04-28
HUP0000935A3 (en) 2002-04-29

Similar Documents

Publication Publication Date Title
IL130900A0 (en) Atropisomers of 3-aryl-4(3H)- quinazolinones and their use as ampa-receptor antagonsts
IL129352A0 (en) Benzimidazole-2- carbamates for the treatment of viral infections and cancer
GB0015235D0 (en) Compositions for the treatment of skin and anorectal conditions
IL127664A (en) Compositions for the treatment and prevention of cachexia
IL134718A0 (en) Treatment of conduct disorder
AP9801414A0 (en) Combination effective for the treatment of impotence
IL130897A0 (en) Atropisomers of 3-heteroaryl-4 (3H)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
IL136110A0 (en) Methods and compositions for the treatment of psoriasis
AU6435398A (en) Prevention and treatment of hepatocellular cancer
AU1556497A (en) Agents for the treatment and prevention of aids
AU2476200A (en) Ribozyme therapy for the treatment and/or prevention of restenosis
GB9808936D0 (en) Combination therapy for the prevention and treatment of osteoporosis
AU7105498A (en) Combination therapy for the prevention and treatment of osteoporosis
HUP9700661A3 (en) Use of alpha-1-adrenoreceptor antagonists for the production of pharmaceuticals for profilacting and treating cancer
AU2663300A (en) Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances
EP0733365A3 (en) Use of benzoquinolin-3-one for the treatment and prevention of prostate cancer
IL135994A0 (en) Combination therapy for the treatment of aids
GB9711848D0 (en) Treatment and prophylaxis of infraction
KR100248098B1 (en) Pharmaceutical composition for the treatment of dementia
EP1143998A4 (en) TREATMENT OF HYPERTENSION
GB9713581D0 (en) Treatment of neuropsychiatric disorders
GB9821610D0 (en) Treatment of neuropsychiatric disorders
ZA9810306B (en) Combination therapy for the treatment of aids
IL121227A0 (en) Composition for the treatment of seborrhea
GB9923551D0 (en) Treatment of neuropsychiatric disorders